Table 10.
Differences in the approach to a third line treatment of CSU in physicians who do and do not follow the guidelines
| Treatment | Compared groups | n | % (n) of physicians, who follow the guidelines | % (n) of physicians, who don’t follow the guidelines | X2 | p |
|---|---|---|---|---|---|---|
| First-generation H1-antihistamines | Administer | 93 | 7.7 (80) | 14.8 (13) | 5.345 | 0.021 |
| No | 1033 | 92.3 (958) | 85.2 (75) | |||
| Second-generation H1-antihistamines at standard dose | Administer | 78 | 6.9 (72) | 6.8 (6) | 0.002 | 0.967 |
| No | 1048 | 93.1 (966) | 93.2 (82) | |||
| Updosed second-generation H1-antihistamines | Administer | 283 | 25.4 (264) | 21.6 (19) | 0.637 | 0.425 |
| No | 843 | 74.6 (774) | 78.4 (69) | |||
| H2-antihistamines (e.g. famotidine or ranitidine) | Administer | 206 | 18.3 (190) | 18.2 (16) | 0.001 | 0.977 |
| No | 920 | 81.7 (848) | 81.8 (72) | |||
| Ciclosporin | Administer | 254 | 23.1 (240) | 15.9 (14) | 2.416 | 0.120 |
| No | 872 | 76.9 (798) | 84.1 (74) | |||
| Omalizumab | Administer | 570 | 51.8 (538) | 36.4 (32) | 7.764 | 0.005 |
| No | 556 | 48.2 (500) | 63.6 (56) | |||
| Montelukast | Administer | 319 | 28.9 (300) | 21.6 (19) | 2.135 | 0.144 |
| No | 807 | 71.1 (738) | 78.4 (69) | |||
| Dapsone | Administer | 91 | 7.8 (81) | 11.4 (10) | 1.384 | 0.239 |
| No | 1035 | 92.2 (957) | 88.6 (78) | |||
| Systemic corticosteroids (for less than 10 days) | Administer | 227 | 20.1 (209) | 20.5 (18) | 0.005 | 0.943 |
| No | 899 | 79.9 (829) | 79.5 (70) | |||
| Systemic corticosteroids (for more than 10 days in a row) | Administer | 146 | 12.7 (132) | 15.9 (14) | 0.733 | 0.392 |
| No | 980 | 87.3 (906) | 84.1 (74) | |||
| Tricyclic antidepressants (e.g. doxepin) | Administer | 134 | 11.7 (121) | 14.8 (13) | 0.751 | 0.386 |
| No | 992 | 88.3 (917) | 85.2 (75) |
Values marked in bold indicate a statistically significant difference (p < 0.05)